Two-Drug immunotherapy cocktail shows promise against tough esophageal cancer
NCT ID NCT07374003
First seen Jan 30, 2026 · Last updated Jun 17, 2026 · Updated 17 times
Summary
This study is testing whether giving two immunotherapy drugs (ipromlimab and tuvonralimab) along with standard chemotherapy before surgery can help people with a certain type of advanced esophageal cancer. The goal is to shrink the tumor enough to make surgery more effective. The study involves 62 adults who have not had prior treatment for their cancer. It is currently active but no longer recruiting new participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED, RESECTABLE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sub-i
Guangdong, GUANGZHOU, 510000, China
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.